Unknown

Dataset Information

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.


ABSTRACT:

Background

Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown.

Methods and results

A multicenter, randomized, double-blind, placebo-controlled trial compared the efficacy and safety of varenicline with placebo for smoking cessation in 714 smokers with stable cardiovascular disease. Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counseling, for 12 weeks. Follow-up lasted 52 weeks. The primary end point was carbon monoxide-confirmed continuous abstinence rate for weeks 9 through 12 (last 4

SUBMITTER: Rigotti NA 

PROVIDER: S-EPMC4096941 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature